Sumitomo Pharma America, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1984-01-01

Employees: 5K

Market Cap: -

Website: http://www.sunovion.com

Clinical Trials

A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Lurasidone 40 mg
Drug: Placebo 40 mg
Drug: Ortho Tri-Cyclen

First Posted Date: 2007-10-26

Last Posted Date: 2011-09-14

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 23

Registration Number: NCT00549666

Locations: 🇺🇸
Covance Global Clinical Pharmacology, Inc., San Diego, California, United States

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Lurasidone HCl

First Posted Date: 2007-10-26

Last Posted Date: 2014-06-11

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 489

Registration Number: NCT00549718

Locations: 🇺🇸
Clinical Innovations, Inc., Costa Mesa, California, United States
🇺🇸
Collaborative Neuroscience Network Inc.,12772 Valley View Street,Suite 3, Garden Grove, California, United States
🇺🇸
Center for Behavioral Health, LLC, Rockville, Maryland, United States

and more 45 locations

A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

Phase 3

Completed

Conditions: Major Depressive Disorder
Insomnia

Interventions: Drug: Placebo
Drug: Eszopiclone
Drug: Venlafaxine

First Posted Date: 2007-02-14

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 678

Registration Number: NCT00435279

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Bronchitis
Emphysema

Interventions: Drug: Arformoterol Tartrate Inhalation Solution
Drug: Arformoterol and Tiotropium
Drug: Tiotropium
Drug: Placebo

First Posted Date: 2007-01-19

Last Posted Date: 2012-06-04

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 235

Registration Number: NCT00424528

SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)

Phase 2

Completed

Conditions: Overactive Bladder Syndrome (OABS)

Interventions: Drug: SMP-986
Drug: Placebo

First Posted Date: 2006-12-11

Last Posted Date: 2014-12-10

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 550

Registration Number: NCT00409539

Locations: 🇪🇪
Tartu University Clinic, Tartu, Estonia
🇵🇱
Medical University of Selesia, Katowice, Poland
🇵🇱
UI.G. Narutowicza 28, Lodz, Poland

and more 59 locations

A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia

Phase 4

Completed

Conditions: Insomnia

Interventions: Drug: Placebo
Drug: Eszopiclone

First Posted Date: 2006-10-11

Last Posted Date: 2016-03-14

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 388

Registration Number: NCT00386334

Locations: 🇺🇸
Anderson Pharmaceutical Research, Anderson, South Carolina, United States

Study of an Evening Dose of Eszopiclone on Next Day Driving Ability & Psychomotor/Memory Function in Healthy Volunteers

Phase 1

Completed

Conditions: Insomnia

Interventions: Drug: Placebo
Drug: Eszopiclone

First Posted Date: 2006-08-24

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 32

Registration Number: NCT00368160

Locations: 🇬🇧
HPRU Medical Research Centre, Guildford, Surrey, United Kingdom

Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis

Phase 3

Completed

Conditions: Insomnia
Arthritis, Rheumatoid

Interventions: Drug: placebo
Drug: Eszopiclone

First Posted Date: 2006-08-24

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 153

Registration Number: NCT00367965

A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

Phase 3

Completed

Conditions: Insomnia
Depressive Disorder, Major

Interventions: Other: Placebo
Drug: Eszopiclone

First Posted Date: 2006-08-24

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 545

Registration Number: NCT00368030

Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability

Phase 3

Completed

Conditions: Primary Insomnia

Interventions: Drug: Eszopiclone
Drug: Placebo

First Posted Date: 2006-08-24

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 32

Registration Number: NCT00368056

Locations: 🇬🇧
HPRU Medical Research Centre, University of Surrey, Guildford, Surrey, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy